培美曲塞二钠联合顺铂治疗晚期肺腺癌的疗效及对血清CYFRA21-1、CA125、CEA、NSE的影响分析  

Efficacy of Pemetrexed Disodium Combined with Cisplatin in the Treat⁃ment of Advanced Lung Adenocarcinoma and Its Effect On Serum CYFRA21-1,CA125,CEA and NSE

作　　者：仇建玲[1] 俞进友[1] 朱正峰[1] QIU Jianling;YU Jinyou;ZHU Zhengfeng(Department of Medical Oncology,Jianhu County People's Hospital,Jianhu 224700,Jiangsu,China)

机构地区：[1]建湖县人民医院肿瘤内科,江苏建湖224700

出　　处：《中外医疗》2024年第19期25-28,共4页China & Foreign Medical Treatment

摘　　要：目的 探讨培美曲塞二钠联合顺铂治疗晚期肺腺癌的疗效,以及对患者血清细胞角质蛋白19片段抗原(Cytokeratin 19 Fragment Antigen 21-1, CYFRA 21-1)、糖类抗原CA125(Carbohydrate Antigen 125, CA125)、癌胚抗原(Carcinoembryonic Antigen, CEA)、神经元特异性烯醇化酶(Neuron Specific Enolase, NSE)的影响。方法 便利选择建湖县人民医院于2019年1月—2023年12月收治的72例晚期肺腺癌患者为研究对象,以随机数字表法分组,对照组(n=36)采用紫杉醇联合顺铂治疗,观察组(n=36)培美曲塞二钠联合顺铂治疗,比较两组的疗效、血清CYFRA21-1、CA125、CEA、NSE水平以及不良反应发生率。结果 观察组的疾病控制率、客观缓解率分别为88.89%和58.33%,均高于对照组的66.67%、33.33%,差异有统计学意义(χ^(2)=5.143、4.532,P均<0.05)。治疗后,观察组的CYFRA21-1、CA125、CEA、NSE水平均低于对照组,差异有统计学意义(P均<0.05)。观察组的不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论 培美曲塞二钠联合顺铂治疗晚期肺腺癌的疗效可靠,患者肿瘤标志物水平下降明显,且药物不良反应小,安全性高。Objective To investigate the efficacy of pemetrexed disodium combined with cisplatin in the treatment of advanced lung adenocarcinoma,and its effect on serum cytokeratin 19 fragment antigen 21-1(CYFRA 21-1),carbo-hydrate antigen 125(CA125),carcinoembryonic antigen(CEA),neuron specific enolase(NSE).Methods A total of 72 patients with advanced lung adenocarcinoma admitted to Jianhu County People's Hospital from January 2019 to De-cember 2023 were conveniently selected as the research objects and grouped by random number table method.The control group(n=36)was treated with paclitaxel combined with cisplatin,and the observation group(n=36)was treated with pemetrexed disodium combined with cisplatin.The efficacy,serum CYFRA21-1,CA125,CEA,NSE levels and incidence of adverse reactions were compared between the two groups.Results The disease control rate and objective remission rate of the observation group were 88.89%and 58.33%,respectively,which were higher than 66.67%and 33.33%of the control group,and the differences were statistically significant(χ^(2)=5.143,4.532,both P<0.05).After treatment,the levels of CYFRA21-1,CA125,CEA and NSE in the observation group were lower than those in the con-trol group,and the differences were statistically significant(all P<0.05).The incidence of adverse reactions in the ob-servation group was lower than that in the control group,the difference was statistically significant(P<0.05).Conclu-sion The efficacy of pemetrexed disodium combined with cisplatin in the treatment of advanced lung adenocarcinoma is reliable,the level of tumor markers in patients decreases significantly,and the adverse drug reactions are small and the safety is high.

关 键 词：晚期肺腺癌 培美曲塞二钠 顺铂 细胞角质蛋白19片段抗原 糖类抗原125 癌胚抗原 

分 类 号：R4[医药卫生—临床医学]